Surf Bio Announces $1.6 Million Non-Dilutive Grant
April 30 2024 - 10:00AM
Business Wire
– Proceeds to Evaluate Novel Formulation
Technology to Improve Thermostability and Deliverability of a
Monoclonal Antibody for Low- and Middle-Income Countries –
Surf Bio, Inc., a biopharmaceutical company commercializing a
novel drug stabilization platform, has received a $1.6 million
grant from the Bill & Melinda Gates Foundation. The grant will
provide funding to evaluate the use of the company’s lead
technology toward increasing the thermostability and deliverability
of a monoclonal antibody in low- and middle-income countries.
Surf Bio’s novel polymer technology enables the formulation of
biologics at higher concentrations and in a more thermostable form
than is currently available. Surf Bio's technology offers
significant opportunities for improving the accessibility of
advanced therapeutics in low- and middle-income countries by
eliminating the requirement for refrigeration and enabling
subcutaneous administration of biologics.
“Surf Bio’s stabilization platform enables pharmaceutical
formulations and delivery in resource-constrained settings that are
not currently possible with today’s technologies,” said Bryan
Mazlish, co-founder and CEO, Surf Bio. “We are thrilled to receive
support from the Bill & Melinda Gates Foundation to advance the
use of our technology to enable greater access to biologics in low-
and middle-income countries.”
Surf Bio has ongoing collaborations with leading multinational
pharmaceutical companies exploring the use of the polymer
technology within their proprietary product pipelines. To date,
in-vitro and in-vivo safety and efficacy data has demonstrated that
Surf Bio’s platform may enable drug developers to produce
temperature stable formulations, very high concentration
subcutaneous formulations, and novel therapeutics formulations that
would not otherwise be possible.
About Surf Bio
Surf Bio is a preclinical biopharmaceutical company that is
leveraging a novel biotechnology platform to develop enhanced
therapeutic solutions for oncology, autoimmune diseases, infectious
diseases, gene therapy, and other therapeutic areas. Surf Bio was
launched by the founders of Bigfoot Biomedical and Mode AGC to
commercialize a breakthrough drug stabilization technology
developed in the Appel lab at Stanford University. Commercially,
the technology is designed to enable reduction of refrigeration
requirements, transition from IV to subcutaneous therapy, and novel
pharmaceutical formulations across a range of therapeutic areas.
For more information about Surf Bio, visit www.surf.bio.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240430358154/en/
media@surf.bio